Comparable stake leader
FEDERATED HERMES, INC.
SEC ownership of aTYR PHARMA INC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001339970.
Disclosed value leader
FEDERATED HERMES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Symbol
- ATYR on Nasdaq
- Ownership evidence mix
- 13D/G and 13F
- Largest current holder
- FEDERATED HERMES, INC.
- Latest large-stake holder
- FEDERATED HERMES, INC.
- Latest evidence date
- 31 Mar 2026
- CIK
- 0001339970
- Location
- San Diego, CA
Ownership snapshot
2 facts
Issuer identity
2 facts
Ownership snapshot
Top shareholders of aTYR PHARMA INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FEDERATED HERMES, INC.
Disclosed value leader
FEDERATED HERMES, INC.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 11%
13D/G row: FEDERATED HERMES, INC.
Showing 1-8 of 50 holder rows.
Quick read
FEDERATED HERMES, INC. leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
FEDERATED HERMES, INC.
11%
BlackRock, Inc.
6.5%
Point72 Asset Management, L.P.
3.2%
FMR LLC
15%
UBS Group AG
3.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FEDERATED HERMES, INC. |
13D/G
13F
Company
|
11%
|
$55,463,739
10,544,437 shares
|
-$21,682,577 | 30 Sep 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
6.5%
|
$29,221,482
5,763,606 shares
|
$0 | 30 Jun 2025 |
| Point72 Asset Management, L.P. |
13D/G
|
3.2%
|
$9,617,297
2,845,354 shares
|
$0 | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
15%
|
$11,471,338
14,706,843 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
3.9%
|
$3,016,426
3,867,213 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.9%
|
$2,973,463
3,812,132 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.4%
|
$1,861,031
2,385,485 shares
|
— | 31 Mar 2026 |
| STATE STREET CORP |
13F
Company
|
1.8%
|
$1,368,431
1,754,399 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$43,363.
Buys
$49,630
Insiders: 1
Sells
$6,267
Insiders: 3
Net
+$43,363
Shares: +93,579
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 100,000
Shares: 6,421
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 100,000 | 0 | $49,630 | $0 | +$49,630 |
| 3-6 | 0 | 6,421 | $0 | $6,267 | -$6,267 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-10 of 10 reporting-owner rows connected to aTYR PHARMA INC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
10
Largest current holder
Paul Schimmel
Net 12M change
+$43,363
Latest report
27 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Paul Schimmel | Director | $393,622 | +$49,630 | +14% | Mixed | 27 May 2026 |
| Sanjay Shukla | President and CEO, Director | $189,085 | -$3,655 | -1.9% | Mixed | 03 Feb 2026 |
| Timothy Coughlin | Director | $98,000 | Filing P/S | 11 May 2026 | ||
| Jill Marie Broadfoot | Chief Financial Officer | $50,575 | -$1,521 | -2.9% | Mixed | 03 Feb 2026 |
| Nancy E. Denyes | General Counsel | $42,489 | -$1,091 | -2.5% | Mixed | 03 Feb 2026 |
| Jane A. Gross | Director | $39,000 | Filing P/S | 11 May 2026 | ||
| Eric Benevich | Director | Mixed | 11 May 2026 | |||
| Sara Zaknoen | Director | Mixed | 11 May 2026 | |||
| Svetlana Lucas | Director | Mixed | 11 May 2026 | |||
| John K. Clarke | Director | Mixed | 22 May 2024 |
Recent insider transactions for aTYR PHARMA INC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Paul Schimmel | ATYR | Common Stock | Purchase | 14.7% | $49,630 | $0.4963 | 100,000 | 779,143 | 27 May 2026 | See Footnote |
| Timothy Coughlin | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Eric Benevich | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Jane A. Gross | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Svetlana Lucas | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Sara Zaknoen | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Paul Schimmel | ATYR | Stock Option (right to buy) | Award | 50,000 | 50,000 | 11 May 2026 | Direct | |||
| Sanjay Shukla | ATYR | Common Stock | Sale | -2.38% | $3,655 | $0.9760 | -3,745 | 153,553 | 04 Feb 2026 | Direct |
| Nancy E. Denyes | ATYR | Common Stock | Sale | -3.26% | $1,091 | $0.9761 | -1,118 | 33,124 | 04 Feb 2026 | Direct |
| Jill Marie Broadfoot | ATYR | Common Stock | Sale | -4.01% | $1,521 | $0.9760 | -1,558 | 37,296 | 04 Feb 2026 | Direct |
| Sanjay Shukla | ATYR | Common Stock | Options Exercise | 7.06% | 10,375 | 157,298 | 03 Feb 2026 | Direct | ||
| Sanjay Shukla | ATYR | Restricted Stock Unit | Options Exercise | -100% | -10,375 | 0 | 03 Feb 2026 | Direct | ||
| Nancy E. Denyes | ATYR | Common Stock | Options Exercise | 8.52% | 2,687 | 34,242 | 03 Feb 2026 | Direct | ||
| Nancy E. Denyes | ATYR | Restricted Stock Unit | Options Exercise | -100% | -2,687 | 0 | 03 Feb 2026 | Direct | ||
| Jill Marie Broadfoot | ATYR | Common Stock | Options Exercise | 10.7% | 3,750 | 38,854 | 03 Feb 2026 | Direct | ||
| Jill Marie Broadfoot | ATYR | Restricted Stock Unit | Options Exercise | -100% | -3,750 | 0 | 03 Feb 2026 | Direct | ||
| Sanjay Shukla | ATYR | Employee Stock Option (right to buy) | Award | 1,500,000 | 1,500,000 | 09 Jan 2026 | Direct | |||
| Jill Marie Broadfoot | ATYR | Employee Stock Option (right to buy) | Award | 412,500 | 412,500 | 09 Jan 2026 | Direct | |||
| Nancy E. Denyes | ATYR | Employee Stock Options (right to buy) | Award | 412,500 | 412,500 | 09 Jan 2026 | Direct | |||
| Paul Schimmel | ATYR | Common Stock | Purchase | 29% | 317,999 | 1,413,023 | 09 Oct 2025 | See Footnote | ||
| Paul Schimmel | ATYR | Common Stock | Purchase | 165.1% | 682,001 | 1,095,024 | 08 Oct 2025 | See Footnote |
* marks a reported price that did not pass the local price check.